Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07263074 · ClinicalTrials.gov registry record · NA

Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories

A NA study of Myeloid Malignancy, sponsored by University of Rochester.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT07263074 is a NA study of Myeloid Malignancy that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 120 participants, below the 336-participant average among 7 other Myeloid Malignancy trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07263074, a NA study of Myeloid Malignancy, is actively recruiting participants, sponsored by University of Rochester.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among patients with myeloid cancers considering allogeneic hematopoietic cell transplantation (alloHCT).

Conditions Studied

Interventions

  • OTHER CHORDS

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2026-01-15
Est. Completion 2028-06-30
Phase NA

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT07263074

The ClinicalTrials.gov registry entry for NCT07263074 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 336-participant average among 7 other Myeloid Malignancy trials with a reported enrollment target (64% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myeloid Malignancy appearing as the primary indexed condition, and to 1 intervention - of which CHORDS is the first listed.

NCT07263074 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT07263074 about?

NCT07263074 is a clinical study titled "Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories". This is a two-arm pilot randomized trial that assesses the feasibility and preliminary efficacy of a digital story and values clarification intervention (Considering alloHCT: Opportunities for Patient Reflection During Decision-Making via Digital Stories \[CHORDS\]) compared to usual care among pati...

What is the current status of trial NCT07263074?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2026-01-15. Estimated completion is 2028-06-30.

What conditions does trial NCT07263074 study?

This clinical trial studies the following conditions: Myeloid Malignancy.

What interventions are being tested in trial NCT07263074?

The interventions under investigation include: CHORDS (OTHER).

Who is sponsoring clinical trial NCT07263074?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07263074 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myeloid Malignancy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.